Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Amazon Biotech has received $250,000 in funding for phase II clinical trials of its candidate AMZ0026 for the treatment of HIV. The company also said that it has received an additional $350,000 in commitments for further funding.
Subscribe to our email newsletter
“This financing brings us a long way toward meeting our funding goals and putting us in position to go forward with our phase II trials upon receipt of FDA approval of our current protocol,” said Dr Michael Kanovsky, president of Amazon.
The company has submitted to the FDA its protocol to test AMZ0026 as an antiviral and immuno-modulating agent in non-treated HIV subjects.
The study design includes non-symptomatic HIV subjects who are not yet treated with highly active anti-retroviral therapy (HAART), with 50% of the subjects receiving placebo and 50% receiving AMZ0026. The six-month study will include the monitoring of T Cell increases and HIV plasma viral load decreases.